Full Press Release Details
Cellectis S.A. Reports Results from Annual General Meeting
Held on June 26, 2018
June 27, 2018 (4:30pm CEST) New York (N.Y.) Cellectis S.A. Annual General Meeting (Euronext Growth: ALCLS
Nasdaq: CLLS) was held on Tuesday, June 26, 2018 in Paris, at its head office.
At the meeting, during which more than 64% of voting rights
were exercised, all the resolutions for which the management recommended a vote in favor, were adopted.
The resolutions adopted by Cellectis
shareholders included notably:
The full results of the vote can be examined on the company s website www.cellectis.com/en/investors/general-meetings/
Cellectis is a clinical-stage
biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing built on its
flagship TALEN technology and pioneering electroporation system PulseAgile Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis goal is to create innovative products in multiple fields and with
various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit
our website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a
registered trademark owned by Cellectis.
For further information, please contact:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic
Communications, 212-896-1241, ckasunich@kcsa.com
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,